Healthcare provider profile · identity verified

Elisha Danzig, DO

Internal Medicine · WATERTOWN, CT · NPI 1396360509

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	260	81
Amlodipine Besylate	Amlodipine Besylate	199	59
Rosuvastatin Calcium	Rosuvastatin Calcium	160	58
Losartan Potassium	Losartan Potassium	146	44
Levothyroxine Sodium	Levothyroxine Sodium	143	40
Lisinopril	Lisinopril	143	43
Metoprolol Succinate	Metoprolol Succinate	104	30
Fluticasone Propionate	Fluticasone Propionate	89	48
Hydrochlorothiazide	Hydrochlorothiazide	77	26
Gabapentin	Gabapentin	74	20
Metformin Hcl	Metformin Hcl	72	23
Albuterol Sulfate Hfa	Albuterol Sulfate	61	17
Trazodone Hcl	Trazodone Hcl	60	19
Lorazepam	Lorazepam	59	15
Tamsulosin Hcl	Tamsulosin Hcl	56	19
Escitalopram Oxalate	Escitalopram Oxalate	55	19
Januvia	Sitagliptin Phosphate	55	13
Furosemide	Furosemide	54	17
Duloxetine Hcl	Duloxetine Hcl	52	15
Metformin Hcl Er	Metformin Hcl	49	16
Alendronate Sodium	Alendronate Sodium	47	suppressed
Meloxicam	Meloxicam	47	19
Montelukast Sodium	Montelukast Sodium	47	12
Allopurinol	Allopurinol	44	18
Omeprazole	Omeprazole	41	14
Pantoprazole Sodium	Pantoprazole Sodium	41	20
Breo Ellipta	Fluticasone/Vilanterol	36	suppressed
Ozempic	Semaglutide	32	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	31	suppressed
Jardiance	Empagliflozin	30	suppressed
Bupropion Xl	Bupropion Hcl	29	suppressed
Ezetimibe	Ezetimibe	29	11
Nystatin	Nystatin	29	11
Sertraline Hcl	Sertraline Hcl	29	11
Tramadol Hcl	Tramadol Hcl	29	14
Trulicity	Dulaglutide	29	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	29	suppressed
Pravastatin Sodium	Pravastatin Sodium	27	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	27	suppressed
Clonazepam	Clonazepam	26	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	26	suppressed
Famotidine	Famotidine	26	suppressed
Ibuprofen	Ibuprofen	26	13
Citalopram Hbr	Citalopram Hydrobromide	25	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	25	22
Paroxetine Hcl	Paroxetine Hcl	24	suppressed
Donepezil Hcl	Donepezil Hcl	23	suppressed
Eliquis	Apixaban	23	suppressed
Simvastatin	Simvastatin	23	suppressed
Prednisone	Prednisone	21	16
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	19
Alprazolam	Alprazolam	19	suppressed
Bupropion Hcl Sr	Bupropion Hcl	19	suppressed
Ramipril	Ramipril	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	suppressed
Azithromycin	Azithromycin	17	17
Chlorthalidone	Chlorthalidone	17	suppressed
Glipizide Er	Glipizide	17	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	16	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Potassium Chloride	Potassium Chloride	16	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	15	suppressed
Midodrine Hcl	Midodrine Hcl	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	14
Synthroid	Levothyroxine Sodium	15	suppressed
Carvedilol	Carvedilol	14	suppressed
Naproxen	Naproxen	14	suppressed
Pregabalin	Pregabalin	14	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Invokana	Canagliflozin	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Valsartan	Valsartan	13	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Meclizine Hcl	Meclizine Hcl	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Oxycodone Hcl	Oxycodone Hcl	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	12	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Memantine Hcl Er	Memantine Hcl	11	suppressed
Topiramate	Topiramate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error